Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eisai
Eisai
Eisai inaugurates new US HQ as closely watched FDA Alzheimer's decision draws near
Fierce Pharma
Sun, 08/21/22 - 09:36 pm
Eisai
headquarters
Alzheimer's disease
FDA
July Brings Layoffs, Job Creation for the Life Sciences
BioSpace
Wed, 08/3/22 - 09:32 pm
layoffs
hirings
Astellas
Pfizer
Eikon Therapeutics
Bayer
Avadel Pharma
Heron Therapeutics
Adverum Biotechnologies
Biogen
Eisai
X4 Pharmaceuticals
Assembly Biosciences
Eisai closing oncology R&D wing H3 Biomedicine for good
Fierce Biotech
Mon, 07/18/22 - 07:23 pm
Eisai
oncology
H3 Biomedicine
layoffs
R&D
Biogen-Eisai go for another biomarker approval in Alzheimer's with lecanemab—and snag priority review
Fierce Biotech
Tue, 07/5/22 - 11:58 pm
Biogen
Eisai
FDA
biomarkers
Alzheimer's disease
lecanemab
ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC
Pharmaforum
Mon, 06/6/22 - 11:52 pm
ASCO 2022
Eisai
antibody-drug conjugate
Bristol Myers Squibb
MORAb-202
Simulation model shows potential clinical value of Eisai drug for patients with early AD
Biopharma Reporter
Mon, 05/9/22 - 10:15 am
Eisai
Alzheimer's disease
lecanemab
Biogen shoves Aduhelm to the side. It's time for lecanemab
Fierce Biotech
Wed, 05/4/22 - 10:33 am
Biogen
Aduhelm
lecanemab
Eisai
Alzheimer's disease
Biogen, Eisai unveil new data on lecanemab, but questions linger on ARIA-E; Spatial biology outfit grabs $33M round
Endpoints
Tue, 03/22/22 - 11:19 pm
Eisai
Biogen
lecanemab
Alzheimer's disease
Eisai hands off responsibility for Aduhelm to Biogen
Pharmaforum
Tue, 03/15/22 - 11:43 am
Eisai
Biogen
Aduhelm
Alzheimer's disease
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon
Fierce Biotech
Mon, 02/14/22 - 12:05 pm
Hemavant
Roivant Sciences
Eisai
MDS
RVT-2001
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Thu, 02/10/22 - 10:16 am
Eisai
Biogen
Aduhelm
Alzheimer's disease
FDA
CMS
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
Biogen and Eisai move forward with investigational Alzheimer's therapy
Biopharma Reporter
Mon, 01/3/22 - 10:45 pm
Biogen
Eisai
lecanemab
Alzheimer's disease
fast track
FDA
Biopharma developments over the Christmas period
EP Vantage
Mon, 01/3/22 - 10:26 am
Alnylam Pharmaceuticals
Bio-Thera Solutions
BioArctic
Biogen
BridgeBio Pharma
Daiichi Sankyo
Eisai
JNJ
Madrigal Pharmaceuticals
Merck
Sutro BioPharma
Tasly Pharmaceutical Group
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA
Fierce Biotech
Tue, 12/28/21 - 10:55 am
Biogen
Eisai
lecanemab
FDA
Aduhelm
fast track
Alzheimer's disease
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators
Fierce Pharma
Wed, 12/22/21 - 11:06 am
Biogen
Eisai
Aduhelm
Japan
Alzheimer's disease
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
Eisai-Biogen Alzheimer's Drug Shows Amyloid Reduction, Disease-Modifying Effect
BioSpace
Thu, 11/11/21 - 10:55 am
Eisai
Biogen
lecanemab
Alzheimer's disease
clinical trials
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s
Pharmaforum
Wed, 10/20/21 - 10:08 am
Altoida
Eisai
clinical trials
augmented reality
Alzheimer's disease
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »